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chronic kidney disease beyond traditional risk
factors: a 6-year nationwide cohort study across
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Background: Hepatitis C virus (HCV) infection and chronic kidney disease (CKD) have high prevalences in Taiwan
and worldwide, but the role of HCV infection in causing CKD remains uncertain. This cohort study aimed to explore
this association.
Methods: This nationwide cohort study examined the association of HCV with CKD by analysis of sampled claims
data from Taiwan National Health Insurance Research Database from 1998 to 2004. ICD-9 diagnosis codes were
used to identify diseases. We extracted data of 3182 subjects who had newly identified HCV infection and no
traditional CKD risk factors and data of randomly selected 12728 matched HCV-uninfected control subjects. Each
subject was tracked for 6 years from the index date to identify incident CKD cases. Cox proportional hazard
regression was used to determine the risk of CKD in the HCV-infected and control groups.
Results: The mean follow-up durations were 5.88 years and 5.92 years for the HCV-infected and control groups,
respectively. Among the sample of 15910 subjects, 251 subjects (1.6%) developed CKD during the 6-year follow-up
period, 64 subjects (2.0%) from the HCV-infected group and 187 subjects (1.5%) from the control group. The incidence
rate of CKD was significantly higher in the HCV-infected group than in the control group (3.42 vs. 2.48 per 1000
person-years, p = 0.02). Multivariate analysis indicated that the HCV-infected group had significantly greater risk for CKD
(adjusted hazard ratio: 1.75, 95% CI: 1.25-2.43, p = 0.0009). This relationship also held for a comparison of HCV-infected
and HCV-uninfected subjects who were younger than 70 years and had none of traditional CKD risk factors.
Conclusions: HCV infection is associated with increased risk for CKD beyond the well-known traditional CKD risk factors.
HCV patients should be informed of their increased risk for development of CKD and should be more closely monitored.
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Chronic kidney disease (CKD) is an increasing public
health problem worldwide. The well-recognized risk fac-
tors for CKD are advanced age [1], diabetes [1], hyper-
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reproduction in any medium, provided the or[2], and cirrhosis [2]. Infectious disease is a recently
identified and under-recognized risk factor for CKD [3].
Hepatitis C has a high prevalence and affects about
170 million people worldwide. The hepatitis C virus
(HCV) mainly causes liver damage, but is also associated
with extra-hepatic diseases, including various types of
glomerulonephritis [4], even in the absence of cirrhosis
[5]. In addition, HCV is more common in CKD patients
who are not yet on dialysis than in the general popula-
tion [6]. Previous research indicated that HCV infection
leads to a rapid decline in the renal function of patients
with diabetic nephropathy [7] and of HCV-infectedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apy [8]. Collectively, these studies suggest that HCV in-
fection has an adverse impact on renal function.
However, there are conflicting results regarding the
effect of HCV on renal function. Two cohort studies
in America reported positive associations of HCV and
CKD in the presence of cirrhosis [9] or ESRD [10] in a
population of veterans, but two other studies of an
urban hospital population and a private health insurance
population reported no association [2,11]. These studies
had adequate sample sizes, but short follow-up periods
(<4 years) and a predominance of males, so the findings
may not apply to the general population. The results of two
other American [12,13] and two Taiwanese cross-sectional
studies [14,15] were also inconsistent. However, another
Taiwanese cohort study [16] indicated a positive association
of HCV with ESRD. A meta-analysis of these observational
studies indicated no association of HCV and CKD [17].
Molecular studies have shown that the HCV core pro-
tein directly inhibits insulin signalling and increases oxi-
dative stress, which can exacerbate insulin resistance
[18] and potentially lead to metabolic syndrome and ad-
vanced cirrhosis [19]. Insulin resistance and oxidative
stress can also lead to endothelial dysfunction and is im-
plicated in the progression of CKD [20]. These molecu-
lar studies provide a biological basis for the hypothesis
that HCV infection increases the risk for CKD.
There is a significant and increasing burden of CKD
and HCV infection in Taiwan, so Taiwan provides an
ideal setting for a study of the relationship of these two
diseases. The HCV population has a high comorbidity
burden [21], and some of these comorbidities are well-
known CKD risk factors, such as diabetes, hypertension,
hyperlipidemia, coronary heart disease, and liver cirrho-
sis. A previous cohort study [2], based on a mean
follow-up time of 25.3 months, reported no relationship
of HCV and CKD. However, a cross-sectional retrospect-
ive analysis [22] reported that the mean time for devel-
opment of CKD in the HCV-infected patients was
74 months. The purpose of the present cohort study was
to examine the causal relationship of HCV and CKD
over the course of 6 years, based on the review of the
Taiwan National Health Insurance Research Database
(NHIRD) and exclusion of HCV-infected subjects with
well-known CKD risk factors.
Methods
Data source
This study used the NHIRD, released by the Taiwan Na-
tional Health Research Institute (NHRI) and available to
all researchers in Taiwan. The NHIRD has been widely
used for epidemiological research [1,16,23-30], including
studies of CKD [1,27] and hepatitis [16,23,24,28]. Taiwan
initiated its National Health Insurance (NHI) program inMarch 1995. This is a compulsory-enrolment, single-
payer system that finances healthcare for all Taiwanese
citizens (~99% of the population) through a registry of
board-certified specialists and contracted medical facil-
ities. The NHIRD is a representative nationwide data-
base that contains all original claims data for one million
beneficiaries from 1996 to 2010, and is a random and
systematic sample of the 25.68 million NHI enrolees.
The NHRI reported no significant differences in age,
gender, or healthcare costs for patients in the NHIRD
and all NHI enrolees. Diagnostic coding by the NHI
program in Taiwan is performed according to ICD-9
codes. Many previous studies have verified the accuracy
of diagnoses in the NHIRD for major diseases such as
diabetes, stroke, hepatitis, CKD, and ESRD [1,16,23,
24,26-30]. This study was evaluated and approved by
Taiwan’s National Health Research Institute Ethics Re-
view Committee. All identifying personal information
was removed from the secondary files before analysis, so
the review board waived the requirement for written in-
formed consent.
Study population
Figure 1 summarized the process used for selection of
cases and controls in this retrospective cohort study. For
the HCV-infected group, we identified all subjects
18 years or older who had a first-time diagnosis of HCV
(ICD-9-CM codes 070.41, 070.44, 070.51, 070.54,
V02.62) [16,23,24,28] over a 7-year period (January 1,
1998 to December 31, 2004) during an outpatient or
hospitalization visit. The index date was defined as the
date of the first diagnosis of HCV. Viral hepatitis is a
significant public health problem in Taiwan, so the gov-
ernment closely monitors HCV infection and establishes
detailed guidelines for diagnosis [24].
Subjects were excluded if they were diagnosed with
HCV before 1998, diagnosed with HBV (ICD-9-CM
codes 070.22, 070.23, 070.32, 070.33, V02.61) [16,23,
24,28] diagnosed with CKD (ICD-9-CM code 585)
[27,31], received renal transplantation (ICD-9-CM code
V420), or were on dialysis therapy, defined as having a
catastrophic illness registration card for ESRD (ICD-9-
CM code 585) [32] from 1996 to the index date. All
Taiwanese patients who develop ESRD and need
long-term dialysis can apply for catastrophic illness
registration cards from the Bureau of National Health
Insurance, and have no copayments for health care. The
diagnostic accuracy of ESRD was confirmed by both
ICD-9 code 585 and inclusion in the Registry for Cata-
strophic Illness Patient Database, a subpart of the
NHIRD [32]. HCV-infected subjects with the following
pre-existing or co-existing comorbidities were excluded:
diabetes (ICD-9-CM code 250), hypertension (ICD-9-
CM codes 401–405), hyperlipidemia (ICD-9-CM codes
Figure 1 Study flow chart. Abbreviations: ESRD, end-stage renal disease; HBV, hepatitis B virus; HCV, hepatitis C virus; ICD-9-CM, International
Classification of Diseases, Ninth Revision, Clinical Modification.
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410–414), and liver cirrhosis (ICD-9-CM codes 571.2,
571.5, 571.6). Previous research indicated that these con-
ditions were associated with HCV through increased in-
sulin resistance or oxidative stress [19,33]. Ultimately,
3182 subjects with newly identified HCV but none of
these comorbidities were enrolled.
The HCV-uninfected control group was selected from
the remaining subjects in the NHIRD. Subjects were ex-
cluded if they were diagnosed with HCV from 1996 to
2010. For each HCV-infected subject, 4 HCV-uninfected
subjects were randomly selected. These uninfected sub-
jects had matching gender, age, and index date (defined
as the same year of the index date of the matched case).A total of 12728 HCV-uninfected control subjects were
enrolled.
Subjects in both groups were tracked for 6 years
(starting from the index date) to identify those who de-
veloped CKD but did not have catastrophic illness regis-
tration cards for ESRD starting renal replacement
therapy. Cases were censored if they died or withdrew
from the insurance program during the follow-up
period. CKD is an important public health problem in
Taiwan, so the CKD Prevention Committee of the
Taiwan Society of Nephrology (TSN) launched a nation-
wide CKD Preventive Project in 2004 for the diagnosis
and close supervision [34]. The TSN adopted the simpli-
fied Modification of Diet in Renal Disease (MDRD)
Table 1 Sociodemographic characteristics and
comorbidities of the hepatitis C virus (HCV)-infected and










Male 1619 (50.9) 6476 (50.9)
Female 1563 (49.1) 6252 (49.1)
Age (year) 1.0000
18–39 1319 (41.5) 5276 (41.5)
40–49 874 (27.5) 3496 (27.5)
50–59 552 (17.3) 2208 (17.3)
60–69 315 (9.9) 1260 (9.9)
≧70 122 (3.8) 488 (3.8)
Diabetes <0.0001
Yes 0 (0) 981 (7.7)
No 3182 (100) 11747 (92.3)
Hypertension <0.0001
Yes 0 (0) 1726 (13.6)
No 3182 (100) 11002 (86.4)
Coronary heart disease <0.0001
Yes 0 (0) 838 (6.6)
No 3182 (100) 11890 (93.4)
Hyperlipidemia <0.0001
Yes 0 (0) 1031 (8.1)
No 3182 (100) 11697 (91.9)
Liver Cirrhosis <0.0001
Yes 0 (0) 96 (0.8)
No 3182 (100) 12632 (99.2)
Geographic region <0.0001
Northern 1017 (32.0) 6157 (48.4)
Central 922 (29.0) 2916 (22.9)
Eastern 81 (2.5) 292 (2.3)
Southern 1162 (36.5) 3362 (26.4)
Urbanization level <0.0001
Urban 818 (25.7) 4076 (32.0)
Suburban 1450 (45.6) 5891 (46.3)
Rural 914 (28.7) 2760 (21.7)
Enrollee category <0.0001
1 1355 (42.6) 5978 (47.0)
2 107 (3.4) 270 (2.1)
3 1250 (39.3) 4367 (34.3)
4 470 (14.8) 2113 (16.6)
Table 1 Sociodemographic characteristics and
comorbidities of the hepatitis C virus (HCV)-infected and
HCV-uninfected control groups in Taiwan, 1998–2004
(n = 15910) (Continued)
No. of health care visits
in 1 year before study
entry
<0.0001
<10 794 (25.0) 5199 (40.8)
11-20 974 (30.6) 3761 (29.5)
21-30 660 (20.7) 1977 (15.5)
31-40 370 (11.6) 850 (6.7)
≧41 384 (12.1) 941 (7.4)
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erular filtration rate (eGFR) [34,35]. Diagnosis of CKD
stages 1 to 5 was according to the National Kidney
Foundation’s Kidney Disease Outcome Quality Initiative
(KDOQI) [36], and used ICD-9 code 585 for national
5-stage CKD surveillance, the same as America [31].
For multivariate analysis, the association of the follow-
ing factors with CKD were calculated: geographic region
of residence (northern, central, southern, and eastern
Taiwan) [1], urbanization level (urban, suburban, and
rural) [27], and socioeconomic status [37]. Enrolee cat-
egory (highest to lowest: EC1, EC2, EC3, and EC4) was
used as a proxy for socioeconomic status [27]. The num-
ber of healthcare visits [25,30] in 1 year before study
entry was also considered as a confounder.
Statistical analysis
All data were analyzed using SAS version 9.2 (SAS Insti-
tute, Inc., Cary, N.C.). A two-sided p-value less than 0.05
was considered statistically significant. A χ2 test was used
to compare categorical variables of the two groups, and
the Kaplan-Meier method was used to estimate the cumu-
lative risk of CKD during the 6-year follow-up. Person-
years of follow-up were calculated for each subject from
the index date to date of CKD diagnosis, date of death, or
the end of the study (6-year follow-up), whichever oc-
curred first. Incidence rate was calculated by dividing the
number of CKD cases by the total person-years of follow-
up. A Cox proportional hazard regression model was used
to estimate hazard ratios (HRs) and 95% confidence
intervals (CIs) after adjustment for covariates. The as-
sumption of proportional hazards was confirmed by
assessment of log minus log survival plots for patterns of
nonproportionality (convergence, divergence, and crossing
of curves) and the proportional assumption was satisfied.
Results
Patient characteristics
Table 1 shows the sociodemographic characteristics and
comorbidities of the HCV-infected and HCV-uninfected
Figure 2 Cumulative risk of CKD in HCV-infected subjects and
HCV-uninfected controls during a 6 year follow-up period.
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Subjects in the HCV-infected group were more likely to
reside in rural areas, live in central, eastern, or southern
Taiwan, have lower socioeconomic status (EC2 or EC3),
and have more healthcare visits (≧11) in 1 year before
study entry (p < 0.0001 for each comparison). As
expected, the HCV-uninfected control group had more
comorbidities (diabetes, hypertension, coronary heart
disease, and liver cirrhosis) because HCV-infected sub-
jects with these comorbidities were excluded.
Cox proportional hazard regression analysis
Table 2 shows the distribution of CKD during the 6-year
follow-up period for the two groups. The NHIRD
tracked the use of all medical services by all subjects
during the entire study period. The HCV-infected group
had a mean follow-up duration of 5.88 years, and the
control group had a mean follow-up duration of
5.92 years. At the end of follow-up, 64 subjects (2.0%)
from the HCV-infected group and 187 subjects (1.5%)
from the control group developed CKD. The incidence
rate of CKD was significantly higher in the HCV-
infected group than in the control group (3.42 vs. 2.48
per 1000 person-years, p = 0.02). The HCV-infected
group also had a higher cumulative risk of CKD than the
control group (Figure 2; p = 0.026). The mean time to
diagnosis of CKD was less in the HCV-infected group
than the control group (2.36 vs. 3.13 years, p = 0.003).
Multivariate analysis with adjustment for age, gender,
comorbidities, geographic region, urbanization level,Table 2 Incidence rate and hazard ratios for chronic
kidney disease (CKD) in the hepatitis C virus (HCV)-
infected and HCV-uninfected control groups during the
6-year follow-up period (n = 15910)





No. of CKD 187 (1.5) 64 (2.0) 0.028








Crude HR (95% CI) 1.00 (reference) 1.38 (1.04-1.83) 0.026
Adjusted HR
(95% CI)b
1.00 (reference) 1.75 (1.25-2.43)† 0.0009
Abbreviations: CI confidence interval, HR hazard ratio.
aPer 1000 person-years.
bAdjusted for age, gender, diabetes, hypertension, coronary heart disease,
hyperlipidemia, liver cirrhosis, geographic region, urbanization level, enrolee
category, and number of healthcare visits in 1 year before study entry.
†Note: Adjusted HR with 95% CI of CKD in association with HCV was
1.97 (1.43-2.73, p < 0.0001) if the number of healthcare visits was not
included in multivariate analysis.enrolee category, and number of healthcare visits in
1 year before study entry indicated that the adjusted haz-
ard ratio (aHR) for CKD during the 6-year follow-up
period was greater in the HCV-infected group than in
the control group (aHR: 1.75; 95% CI: 1.25-2.43,
p = 0.0009). If the number of healthcare visits was not
included in this multivariate analysis, the aHR for CKD
was 1.97 (95% CI: 1.43-2.73, p < 0.0001).
Cox proportional hazard regression analysis of subjects
younger than 70 years old and without the above-
mentioned comorbidities at baseline
Tsui et al. [10] demonstrated that HCV-infected patients
younger than 70 years, but not older than 70 years, had
increased risk for development of ESRD. Thus, we used
a sensitivity test to analyze the association between HCV
and CKD for the subjects younger than 70 years and
without the above-mentioned comorbidities at baseline
(Table 3). This analysis consisted of 3060 HCV-infected
subjects and 9700 HCV-uninfected subjects. At the end
of the follow-up, the HCV-infected group had a signifi-
cantly higher incidence rate and aHR for CKD (aHR:
2.12, 95% CI: 1.44-3.13, p = 0.0002), and this aHR was
slightly higher than that for all subjects (2.12 vs. 1.75).
Discussion
Many previous cohort studies have examined the associ-
ation of HCV and CKD, but the results have been
contradictory. The results of the present cohort study,
which had a longer follow-up period (6 years) than these
previous studies, indicate that HCV is a significant risk
factor for CKD in the absence of traditional CKD risk
factors, even after controlling for potential confounders.
Our study has a number of strengths that should be
noted. First, the study population was taken from a large
computerized database, and was representative of the
population of Taiwan (rather than a specific region), so
Table 3 Incidence rate and hazard ratios for chronic
kidney disease (CKD) in the hepatitis C virus (HCV)-
infected and HCV-uninfected control groups younger
than 70 years old and without comorbidities at baseline




N (%) (n = 3060) N (%)
No. of CKD 58 (0.6) 56 (1.8) <0.0001




Incidence ratea 1.00 3.11 <0.0001
Crude HR (95% CI) 1.00 (reference) 3.09 (2.14-4.47) <0.0001
Adjusted HR (95% CI)b 1.00 (reference) 2.12 (1.44-3.13) 0.0002
Abbreviations: CI confidence interval, HR hazard ratio.
aPer 1000 person-years.
bAdjusted for age, gender, geographic region, urbanization level, enrollee
category, and number of health care visits in 1 year before study entry.
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Taiwan. Second, selection bias was not significant be-
cause we included subjects with newly identified HCV
from 1998 to 2004 and we selected HCV-uninfected
controls from a simple random sample of the insured
general population. Third, recall bias was not significant
because we identified traditional CKD risk factors from
this database. Fourth, retrospective inclusion of HCV-
infected subjects without coexisting traditional risk fac-
tors and retrospective exclusion of individuals with a
previous history of CKD allowed us to exclusively study
newly diagnosed cases of CKD. This provided a more re-
liable assessment of the relationship between HCV and
CKD risk. Fifth, sensitivity analysis, which excluded sub-
jects older than 70 years and without comorbidities at
baseline, also indicated a positive association of HCV
and CKD. Sixth, we also considered urbanization level
and socioeconomic status to reduce environmental ef-
fects [29]. Seventh, in contrast to previous cohort studies
[9-12,16], our multivariate analysis considered the num-
ber of healthcare visits to minimize detection bias, be-
cause HCV-positive patients might have been more
closely followed and therefore received earlier diagnosis
of CKD. Previous reports also used this method [25,30].
Our results indicated a decreased aHR after adjusting
for the number of healthcare visits (aHR: 1.97, 95%
CI: 1.43-2.73, p < 0.0001 vs. aHR: 1.75, 95% CI, 1.25-2.43,
p = 0.0009). This indicates that clinicians should consider
this as a potential confounding factor in future studies
[30]. This information provides reassurance that
HCV(+) is associated with an increased risk of CKD, and
this association noted in our study is not merely due to
an early detection of CKD in patients with HCV(+).
Finally, the NHIRD is a large database that providessufficient statistical power and good follow-up informa-
tion for valid assessment of the relationship of HCV
infection and CKD.
In the current study, the incidence rate of CKD in
HCV-infected subjects was 0.9 per 1000 person-years
higher than that in HCV-uninfected controls. This cor-
responds to approximately one additional case of CKD
annually per 1000 HCV-infected subjects. Moreover,
HCV-infected subjects without comorbidities were 1.75-
fold more likely to develop CKD after adjustment for
confounders, and to develop CKD nine months earlier
than HCV-uninfected controls with comorbidities. These
findings have important implications for prevention of
CKD in Taiwan, where the prevalence of CKD is 11.9%
[37] and the prevalence of HCV is 2-3% [38]. In particu-
lar, our results suggest that HCV-infected subjects
should be routinely screened for CKD. However, future
studies are needed to assess the effect of HCV eradica-
tion on the progression of CKD.
The risk of developing CKD in our HCV-infected sub-
jects without traditional comorbidities (aHR: 1.75, 95%
CI: 1.25-2.43) was higher than that in an American cohort
of veterans (aHR: 1.3, 95% CI: 1.23-1.37) [9], a population
that had higher prevalence of several CKD risk factors
than our population. This difference may be related to dif-
ferences in follow-up duration, comorbidities, and number
of healthcare visits. However, our results are inconsistent
with two other American cohort studies, one of an urban
hospital [11] and another of a private health insurance
population [2]. This difference may be attributed to the
shorter follow-up durations of these two studies. Most
kidney diseases have prolonged natural histories, so we be-
lieve that the strength and magnitude of the associations
in our study are more valid because we used a 6 year
follow-up period. In addition, two cross-sectional studies
of a mostly female population in southern Taiwan [14,15],
a region with a higher prevalence of HCV, also showed
conflicting results, underlying the importance of the study
population. A previous study of Asian HCV patients indi-
cated that there were approximately equal numbers of
males and females [39], consistent with our HCV cohort.
To date, there are two claim-based national cohort
studies which employed ICD-9 coding that have vali-
dated an increased incidence and risk of developing
ESRD in HCV(+) patients. A study of an American vet-
eran population with male predominance [10] reported
an incidence of 4.26 per 1000 person-years and an aHR
of 1.68 (95% CI: 1.54-1.82). A study of the Taiwanese
general population with similar sex ratio [16] reported
an incidence of 2.36 per 1000 person-years and an aHR
of 1.53 (95% CI: 1.17-2.01). The different incidences and
aHRs for ESRD in these two studies may be due to the
different gender ratios, because male CKD patients tend
to experience more rapid deterioration of renal function
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these two studies. Tsui et al. [10] validated that ESRD
risk was independent of cirrhosis, but Su et al. [16] did
not examine this issue. Su et al. validated a higher risk of
ESRD in HCV(+) males than females, but Tsui et al. did
not examine this. Tsui et al. indicated that HCV(+) pa-
tients had a lower prevalence of comorbidities at base-
line than controls, and did not consider the Charlson
comorbidity index (CCI) in the analysis, but Su et al. in-
dicated that HCV(+) patients had a higher prevalence of
comorbidities at baseline than controls and explicitly
considered CCI in the analysis. Although CCI is an
established method for summarizing the overall effect of
comorbidities, it was developed for mortality analysis
based on short-term outcomes of small samples of hos-
pitalized patients, so should not be viewed as definitive
for other types of studies [41]. In particular, Liu et al.
[42] questioned whether the CCI accurately describes
the comorbidity burden for ESRD and CKD patients and
Schneeweiss et al. [43] concluded that comorbidity
scores are unlikely to provide satisfactory confounder
adjustments and do not standardize confounder adjust-
ment across studies. Moreover, in addition to the present
study, several well-known national claim-based studies
in Taiwan [24,28,29] and elsewhere [2,33] that employed
ICD-9 coding also did not adopt the CCI in their multi-
variate analyses. In the present study, subjects with trad-
itional CKD risk factors were excluded from the HCV
group but included in the control group. Thus, the num-
ber of comorbidities was significantly higher in the
control group than the HCV group. This difference also
strengthens our finding of a positive association between
HCV and CKD. Our prior research validated this study
design [27].
In the present study, the positive association between
HCV and CKD in the absence of cirrhosis suggests that
HCV may be directly responsible for renal injury. This
result is consistent with a previous study which reported
that a subset of HCV-infected subjects had renal in-
volvement in the absence of cirrhosis [5]. The role of
HCV in the pathogenesis of renal injury is uncertain,
but we can suggest several possible mechanisms based
on laboratory studies: (i) HCV may have direct cyto-
pathic effects on renal parenchyma [44]; (ii) the patient’s
systemic immune response to HCV infection is mediated
by cryoglobulin, and this may lead to the formation of
HCV-antibody immune complexes that disrupt renal
function [44]; (iii) HCV may increase the expression of
toll-like receptors in renal glomeruli [44]; and (iv) HCV
may increase insulin resistance [18,19], leading to
intrarenal overproduction of insulin-like growth factor-1
and transforming growth factor β, thus intensifying oxi-
dative stress [20]. Some studies have also shown that the
levels of inflammatory markers (interleukin 6, tumornecrosis factor α, highly sensitive C-reactive protein) are
higher in HCV-infected patients than HCV-uninfected
controls [19,33].
There are several limitations to this study. First, we
did not consider CKD risk factors such as use of herbal
supplements and analgesics and smoking because these
data were not available in the NHIRD. Therefore, the as-
sociation between HCV and CKD may be partially
explained by residual confounding of these factors. How-
ever, previous research indicated that these factors con-
tribute far less to CKD than traditional risk factors
(aging, diabetes, and hypertension) [26], so their inclu-
sion is unlikely to affect the results. Second, the diagno-
ses of HCV, CKD, and other comorbidities are based on
ICD-9 codes, and misclassification is possible. However,
many previous national cohort studies used ICD-9 codes
for patients with chronic diseases and have validated this
approach [1,2,16,23,24,26-30,33,45], so misclassification
(if any) was likely to be random and thereby lead to un-
derestimates of associations [25]. Furthermore, the NHI
Bureau of Taiwan randomly reviews the charts and
audits medical charges and imposes heavy penalties for
inappropriate charges or malpractice. It is generally be-
lieved that these checks and balances ensure accurate
coding [46] to minimize ascertainment bias. Claims data
can be used to accurately identify patients with CKD be-
cause of a high positive predictive value (97.5%) [45].
Previous studies have documented the similarity of CKD
diagnosis based on claims data of large administrative
data sets and on eGFR [1]. Also, the prevalence of
claims-identified CKD has risen substantially since 1999
because of increased recognition and coding of earlier-
stage CKD [31]. Therefore, we believe that patients with
5-stage CKD were identified during the 6-year follow-
up, through implementation of the nationwide CKD
Preventive Project since 2004 and 5-stage CKD classifi-
cation according to the simplified MDRD equation since
late 2005. Third, patients with sub-clinical HCV infec-
tion may have been included in our HCV-uninfected
controls. However, if HCV is causally associated with
CKD, this misclassification would further strengthen our
findings [16,28]. Moreover, the overall seroprevalence of
anti-HCV in Taiwan has been estimated as 2 ~ 3% [38]
and the prevalence of HCV in our cohort was within this
range (2.1%). Therefore, the positive association between
HCV and CKD in our cohort is relatively solid. Fourth,
laboratory data (e.g. serum HCV RNA, creatinine levels,
HCV genotype) is not available in the NHIRD. Thus, we
could not consider the effects of CKD severity, viral
count, or viral genotype. Notably, previous research indi-
cates that ~78% HCV-infected patients have chronic
viremia [47]. Fifth, our use of ICD-9 coding for diagnosis
of HCV infection is likely to have excluded some sub-
jects with mild disease, leading to severity bias that
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hepatitis is a major health problem and liver cancer is a
leading cause of cancer deaths in Taiwan, so the govern-
ment has developed rigorous guidelines for diagnosis
[24] and has established programs for extensive commu-
nity screening [16]. Hence, most HCV cases in Taiwan
are asymptomatic and are identified through extensive
screening programs rather than severe HCV cases diag-
nosed in hospitals. Finally, as with any observational
study, potential unmeasured confounders may exist in
cases and controls. However, we controlled for the
confounding effect of medical attention by introducing the
number of healthcare visits into the multivariate regres-
sion model [25]. Nonetheless, given the magnitude and
statistical significance of the observed effects in this study,
this limitation is unlikely to compromise our results.
Conclusions
In summary, this nationwide 6-year follow-up cohort study
indicates that there is a significant and independent associ-
ation between HCV infection and CKD risk in the absence
of traditional CKD risk factors. HCV-infected patients
should be made aware of their increased risk for CKD and
should be more carefully monitored for development of
CKD. Further interventional studies are needed to evaluate
the impact of HCV therapy on the progression of CKD.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: YCC. Contributed reagents/
materials/analysis tools: SKH, YCS. Performed the experiments: YCC. Analyzed
the data: YCC, WYC, SKH, YCS. Wrote the paper: YCC. Provided constructive
opinions and suggestions: YCC, WYC, SKH, YCS, SJH. Study supervision: SKH,
YCS. All authors read and approved the final manuscript.
Acknowledgements
This study is based partly on secondary data from the National Health Insurance
Research Database provided by the Bureau of National Health Insurance,
Department of Health, Taiwan. The interpretations and conclusions herein do
not represent the views of the Bureau of National Health Insurance, Department
of Health, or National Health Research Institutes.
Author details
1Divisions of Nephrology, Department of Internal Medicine, Buddhist Dalin
Tzu Chi General Hospital, Chiayi and School of Medicine, Tzu Chi University,
Hualien, Taiwan. 2Department of Radiation Oncology, Buddhist Dalin Tzu Chi
General Hospital, Chiayi, and School of Medicine, Tzu Chi University, Hualien,
Taiwan. 3Divisions of Hematology-Oncology, Department of Internal
Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi and School of
Medicine, Tzu Chi University, Hualien, Taiwan. 4Division of Nephrology,
Department of Internal Medicine, Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan.
Received: 12 March 2013 Accepted: 29 July 2013
Published: 6 September 2013
References
1. Kuo HW, Tsai SS, Tiao MM, Yang CY: Epidemiological features of CKD in
Taiwan. Am J Kidney Dis 2007, 49:46–55.2. Asrani SK, Buchanan P, Pinsky B, Rey LR, Schnitzler M, Kanwal F: Lack of
association between hepatitis C infection and chronic kidney disease.
Clin Gastroenterol Hepatol 2010, 8:79–84.
3. Yang CW: Leptospirosis renal disease: understanding the initiation by
toll-like receptors. Kidney Int 2007, 72:918–925.
4. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH: Hepatitis C and
renal disease: an update. Am J Kidney Dis 2003, 42:631–657.
5. Arase Y, Ikeda K, Murashima N, Koida I, Suzuki Y, Saitoh S, Kobayashi M,
Kobayashi M, Kobayashi M, Kumada H: Glomerulonephritis in autopsy
cases with hepatitis C virus infection. Intern Med 1998, 37:836–840.
6. Garcia-Valdecasas J, Bernal C, Garcia F, Cerezo S, Umana WO, von Albertini
B, Kimmel PL: Epidemiology of hepatitis C virus infection in patients with
renal disease. J Am Soc Nephrol 1994, 5:186–192.
7. Soma J, Saito T, Taguma Y, Sugimura K, Ogawa S, Ito S: High prevalence
and adverse effect of hepatitis C virus infection in type II
diabetic-related nephropathy. J Am Soc Nephrol 2000, 11:690–699.
8. Arase Y, Suzuki F, Kawamura Y, Akuta N, Sezaki H, Hosaka T, Ogawa K, Imai
N, Seko Y, Saito S, Ikeda K, Kobayashi M, Kumada H: Development rate of
chronic kidney disease in hepatitis C virus patients with advanced
fibrosis after interferon therapy. Hepatol Res 2011, 41:946–954.
9. Butt AA, Wang X, Fried LF: HCV infection and the incidence of CKD.
Am J Kidney Dis 2011, 57:396–402.
10. Tsui JI, Vittinghoff E, Shlipak MG, Rodriguez RA, O’Hare AM: Association of
hepatitis C seropositivity with increased risk for developing end-stage
renal disease. Arch Intern Med 2007, 167:1271–1276.
11. Moe SM, Pampalone AJ, Ofner S, Rosenman M, Teal E, Hui SL: Association
of hepatitis C virus infection with prevalence and development of
kidney disease. Am J Kidney Dis 2008, 51:885–892.
12. Tsui JI, Vittinghoff E, Shlipak MG, O’Hare AM: Relationship between hepatitis C
and chronic kidney disease: results from the Third National Health and
Nutrition Examination Survey. J Am Soc Nephrol 2006, 17:1168–1174.
13. Dalrymple LS, Koepsell T, Sampson J, Kestenbaum B: Hepatitis C virus
infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol
2007, 2:715–721.
14. Lee JJ, Lin MY, Yang YH, Lu SN, Chen HC, Hwang SJ: Association of
hepatitis C and B virus infection with CKD in an endemic area in Taiwan:
a cross-sectional study. Am J Kidney Dis 2010, 56:23–31.
15. Lin MY, Chiu YW, Lee CH, Yu HY, Chen HC, Wu MT, Hwang SJ: Factors
associated with CKD in the elderly and nonelderly population. Clin J Am
Soc Nephrol 2013, 8:33–40.
16. Su FH, Su CT, Chang SN, Chen PC, Sung FC, Lin CC, Yeh CC: Association of
hepatitis C virus infection with risk of ESRD: a population-based study.
Am J Kidney Dis 2012, 60:553–560.
17. Fabrizi F, Martin P, Dixit V, Messa P: Hepatitis C virus infection and kidney
disease: a meta-analysis. Clin J Am Soc Nephrol 2012, 7:549–557.
18. Serfaty L, Capeau J: Hepatitis C, insulin resistance and diabetes: clinical
and pathogenic data. Liver Int 2009, 29(Suppl 2):13–25.
19. Harrison SA: Insulin resistance among patients with chronic hepatitis C:
etiology and impact on treatment. Clin Gastroenterol Hepatol 2008, 6:864–876.
20. Sarafidis PA, Ruilope LM: Insulin resistance, hyperinsulinemia, and
renal injury: mechanisms and implications. Am J Nephrol 2006,
26:232–244.
21. Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM: The high
comorbidity burden of the hepatitis C virus infected population in the
United States. BMC Infect Dis 2012, 12:86.
22. Satapathy SK, Lingisetty CS, Williams S: Higher prevalence of chronic
kidney disease and shorter renal survival in patients with chronic
hepatitis C virus infection. Hepatol Int 2012, 6(21):369–378.
23. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT: Association between
nucleoside analogues and risk of hepatitis B virus-related hepatocellular
carcinoma recurrence following liver resection. JAMA 2012, 308:1906–1914.
24. Tsan YT, Lee CH, Wang JD, Chen PC: Statins and the risk of hepatocellular
carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012,
30:623–630.
25. Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY: Statins are associated with a
reduced risk of gastric cancer: a population-based case–control study.
Am J Gastroenterol 2011, 106:2098–2103.
26. Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, Wang JD: Risks of kidney failure
associated with consumption of herbal products containing Mu Tong or
Fangchi: a population-based case–control study. Am J Kidney Dis 2010,
55:507–518.
Chen et al. BMC Nephrology 2013, 14:187 Page 9 of 9
http://www.biomedcentral.com/1471-2369/14/18727. Chen YC, Su YC, Lee CC, Huang YS, Hwang SJ: Chronic kidney disease itself is a
causal risk factor for stroke beyond traditional cardiovascular risk factors: a
nationwide cohort study in Taiwan. PLoS One 2012, 7:e36332.
28. Su FH, Chang SN, Chen PC, Sung FC, Huang SF, Chiou HY, Su CT, Lin CC,
Yeh CC: Positive association between hepatitis C infection and oral
cavity cancer: a nationwide population-based cohort study in Taiwan.
PLoS One 2012, 7:e48109.
29. Sheu JJ, Kang JH, Lin HC: Hyperthyroidism and risk of ischemic stroke in
young adults: a 5-year follow-up study. Stroke 2010, 41:961–966.
30. Sun Y, Chang YH, Chen HF, Su YH, Su HF, Li CY: Risk of Parkinson disease
onset in patients with diabetes: a 9-year population-based cohort study
with age and sex stratifications. Diabetes Care 2012, 35:1047–1049.
31. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B,
Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Li Q, Li S, Li S, Peng
Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun
D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, et al: United States
Renal Data System 2008 Annual Data Report. Am J Kidney Dis 2009,
53(1 Suppl):S1–S374.
32. Bureau of National Health Insurance: Executive Yuan, Taiwan: Department of
Health. Available: http://www.nhi.gov.tw. Accessed 17 June 2013.
33. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC: Hepatitis C virus
infection and the risk of coronary disease. Clin Infect Dis 2009, 49:225–232.
34. Taiwan society of nephrology. Available: http://www.tsn.org.tw. Accessed
17 June 2013.
35. Hsu CC, Hwang SJ, Wen CP, Chang HY, Chen T, Shiu RS, Horng SS, Chang
YK, Yang WC: High prevalence and low awareness of CKD in Taiwan: a
study on the relationship between serum creatinine and awareness from
a nationally representative survey. Am J Kidney Dis 2006, 48:727–738.
36. National Kidney Foundation: K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and stratification.
Am J Kidney Dis 2002, 39(2):S1–S266.
37. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang PH, Hsu
CC, Sung PK, Hsu YH, Wen SF: All-cause mortality attributable to chronic
kidney disease: a prospective cohort study based on 462 293 adults in
Taiwan. Lancet 2008, 371:2173–2182.
38. Chen CJ, Wang LY, Chien YC: News from Taiwan. Hepatology 2004, 39:1196.
39. Celona AF, Yu MC, Prakash M, Kuo T, Bonacini M: Hepatitis C in a Los Angeles
public hepatitis clinic: demographic and biochemical differences associated
with race-ethnicity. Clin Gastroenterol Hepatol 2004, 2:459–462.
40. Silbiger SR, Neugarten J: The impact of gender on the progression of
chronic renal disease. Am J Kidney Dis 1995, 25:515–533.
41. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chronic Dis 1987, 40:373–383.
42. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ: An improved
comorbidity index for outcome analyses among dialysis patients.
Kidney Int 2010, 77:141–151.
43. Schneeweiss S, Maclure M: Use of comorbidity scores for control of
confounding in studies using administrative databases. Int J Epidemiol
2000, 29:891–898.
44. Barsoum RS: Hepatitis C virus: from entry to renal injury–facts and
potentials. Nephrol Dial Transplant 2007, 22:1840–1848.
45. Collins AJ, Chen SC, Gilbertson DT, Foley RN: CKD surveillance using
administrative data: impact on the health care system. Am J Kidney Dis
2009, 53:S27–S36.
46. Cheng TM: Taiwan’s new national health insurance program: genesis and
experience so far. Health Aff 2003, 22:61–76.
47. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ:
The prevalence of hepatitis C virus infection in the United States,
1999 through 2002. Ann Intern Med 2006, 144:705–714.
doi:10.1186/1471-2369-14-187
Cite this article as: Chen et al.: Hepatitis C virus itself is a causal risk
factor for chronic kidney disease beyond traditional risk factors: a 6-year
nationwide cohort study across Taiwan. BMC Nephrology 2013 14:187.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
